- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05860933
A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants
January 23, 2024 updated by: Eli Lilly and Company
A Phase 1 Study to Evaluate the Effects of Multiple Doses of Itraconazole or Carbamazepine on the Single-Dose Pharmacokinetics of LY3537982 in Healthy Adult Subjects
The main purpose of this study is to evaluate the effect of itraconazole and carbamazepine on LY3537982 when administered as multiple doses by conducting the blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in adult healthy participants.
The study will also evaluate the safety and tolerability of LY3537982.
The study is conducted in two parts.
Participants will stay in the research center during the study, which will last about 11 and 15 days for part 1 and part 2, respectively, not including screening.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Patient Advocacy
- Phone Number: 855-569-6305
- Email: clinicaltrials@loxooncology.com
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78209
- ICON Early Development Services
-
-
Utah
-
Salt Lake City, Utah, United States, 84124
- ICON Early Development Services
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease
- Body mass index (BMI): 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
Exclusion Criteria:
- Females who are lactating or of childbearing potential
- Clinically significant history of any drug sensitivity, drug allergy, or food allergy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LY3537982 + Itraconazole (Part 1)
LY3537982 administered orally alone followed by LY3537982 administered in combination with itraconazole orally.
|
Administered orally.
Administered orally.
|
Experimental: LY3537982 + Carbamazepine (Part 2)
LY3537982 administered orally alone followed by LY3537982 administered in combination with carbamazepine orally.
|
Administered orally.
Administered orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3537982 administered with or without itraconazole
Time Frame: Predose on day 1 up to 72 hours postdose on day 9
|
PK: Cmax of LY3537982 administered with or without itraconazole
|
Predose on day 1 up to 72 hours postdose on day 9
|
PK: Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC[0-inf]) of LY3537982 administered with or without itraconazole
Time Frame: Predose on day 1 up to 72 hours postdose on day 9
|
PK: AUC[0-inf] of LY3537982 administered with or without itraconazole
|
Predose on day 1 up to 72 hours postdose on day 9
|
PK: AUC from Time 0 to time of the last measurable concentration (AUClast) of LY3537982 administered with or without itraconazole
Time Frame: Predose on day 1 up to 72 hours postdose on day 9
|
PK: AUClast of LY3537982 administered with or without itraconazole
|
Predose on day 1 up to 72 hours postdose on day 9
|
PK: Cmax of LY3537982 administered with or without carbamazepine
Time Frame: Predose on day 1 up to 72 hours postdose on day 13
|
PK: Cmax of LY3537982 administered with or without carbamazepine
|
Predose on day 1 up to 72 hours postdose on day 13
|
PK: AUC[0-inf] of LY3537982 administered with or without carbamazepine
Time Frame: Predose on day 1 up to 72 hours postdose on day 13
|
PK: AUC[0-inf] of LY3537982 administered with or without carbamazepine
|
Predose on day 1 up to 72 hours postdose on day 13
|
PK: AUClast of LY3537982 administered with or without carbamazepine
Time Frame: Predose on day 1 up to 72 hours postdose on day 13
|
PK: AUClast of LY3537982 administered with or without carbamazepine
|
Predose on day 1 up to 72 hours postdose on day 13
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Yingying Guo-Avrutin, MD, PhD, Loxo Oncology, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 8, 2023
Primary Completion (Actual)
August 28, 2023
Study Completion (Actual)
August 28, 2023
Study Registration Dates
First Submitted
May 8, 2023
First Submitted That Met QC Criteria
May 8, 2023
First Posted (Actual)
May 16, 2023
Study Record Updates
Last Update Posted (Estimated)
January 24, 2024
Last Update Submitted That Met QC Criteria
January 23, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Anticonvulsants
- Sodium Channel Blockers
- Antimanic Agents
- Hormone Antagonists
- Cytochrome P-450 Enzyme Inducers
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Cytochrome P-450 CYP3A Inducers
- 14-alpha Demethylase Inhibitors
- Itraconazole
- Carbamazepine
Other Study ID Numbers
- LOXO-RAS-22002
- J3M-OX-JZQD (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Itraconazole
-
University of Maryland, BaltimoreCompleted
-
University of Alabama at BirminghamWashington University School of Medicine; University of California, DavisCompletedInvasive Fungal InfectionsUnited States, Panama
-
Johns Hopkins UniversityMemorial Sloan Kettering Cancer CenterCompleted
-
Sara BotrosCompleted
-
Pulmatrix Inc.Completed
-
University of Kansas Medical CenterUniversity of Texas, Southwestern Medical Center at DallasRecruitingBarrett Oesophagitis With DysplasiaUnited States
-
Halcygen Pharmaceuticals LimitedCompletedOnychomycosisUnited States
-
H. Lundbeck A/SCompletedCytochrome P450 InteractionUnited Kingdom, United States
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedOnychomycosisUnited States, South Africa, Canada, Dominican Republic, Ecuador, Honduras, Panama
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedNon-small Cell Lung Cancer MetastaticUnited States